TrialResults-center.org

Menu

Atopaxar antiplatelets drug

Acute coronary syndrome

ACS (excluding AMI): 1 trials - J-LANCELOT

atopaxar vs placebo

No demonstrated result

Endpoint	TE [95% CI]	p val	I2	n	k	trials
all cause death, MI, stroke	no data
refractory ischemia	no data
cardiovascular events	no data
myocardial infarction (fatal and non fatal)	no data
stroke (fatal and non fatal)	no data
ischemic stroke	no data
Vascular death	no data
Non vascular death	no data
Non fatal MI	no data
Revascularization	no data
All cause death	no data
Non fatal stroke	no data
fatal bleeding	no data
Bleeding	no data
Major bleeding	no data

TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients

See more clinical conditions

All type of patients: 2 trials - LANCELOT ACS - J-LANCELOT

atopaxar vs placebo

No demonstrated result

Endpoint	TE [95% CI]	p val	I2	n	k	trials
all cause death, MI, stroke	no data
refractory ischemia	no data
cardiovascular events	no data
myocardial infarction (fatal and non fatal)	no data
stroke (fatal and non fatal)	no data
ischemic stroke	no data
Vascular death	no data
Non vascular death	no data
Non fatal MI	no data
Revascularization	no data
All cause death	no data
Non fatal stroke	no data
fatal bleeding	no data
Bleeding	no data
Major bleeding	no data

TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients

Modal title

- About - Browse pathology | treatment - Site map - Credits Made with in Lyon - Contact us - Privacy policy -